NEW YORK, July 10, 2017 /PRNewswire/ --
If you want a Stock Review on HZNP, MYL, NBIX or RIGL then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. The Generic Drugs market can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the market can be classified into cardiovascular products, anti-infective
Dublin, Ireland headquartered Horizon Pharma PLC's stock finished last Friday's session 0.40% lower at $12.33. A total volume of 2.57 million shares was traded. The Company's shares have advanced 11.28% in the past month. The stock is trading above its 50-day moving average by 6.09%. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have a Relative Strength Index (RSI) of 65.22.
On June 16th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $13 per share.
On June 23rd, 2017, Horizon Pharma announced that it has completed the sale of a European subsidiary, which owns the marketing rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe and the EMEA regions, to Chiesi Farmaceutici S.p.A. for an upfront payment of $72.2 million, with additional potential milestone payments based on sales targets. Visit us today and access your complete report on HZNP for free at:
On Friday, shares in Hatfield, the UK-based Mylan N.V. ended the session 0.11% lower at $37.61. The stock recorded a trading volume of 2.75 million shares. The Company's shares are trading 2.27% below their 50-day moving average. Moreover, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 43.02.
On June 16th, 2017, research firm Cantor Fitzgerald initiated a 'Neutral' rating on the Company's stock, with a target price of $41 per share. The complimentary research report on MYL can be accessed at:
San Diego, California headquartered Neurocrine Biosciences Inc.'s shares declined 0.23%, closing the session at $46.73 with a total trading volume of 777,611 shares. The stock has gained 4.68% in the last one month, 16.13% over the previous three months, and 20.75% on an YTD basis. The stock is trading 1.79% above their 200-day moving average. Additionally, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have an RSI of 49.42. Register for free on DailyStockTracker.com and download the research report on NBIX at:
Last Friday at the close, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. recorded a trading volume of 1.35 million shares, which was above their three months average volume of 950,270 shares. The stock ended the session 1.12% lower at $2.66. The Company's shares have advanced 13.19% in the past month and 11.76% since the start of this year. The stock is trading above its 50-day moving average by 1.52%. Furthermore, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 49.58.
On June 19th, 2017, Rigel Pharma announced that the US Food and Drug Administration (FDA) has filed its New Drug Application for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP). The Company expects the action date for the FDA to complete its review will be April 17th, 2018 under the Prescription Drug User Fee Act. The FDA previously granted Orphan Drug designation to TAVALISSE™ for the treatment of patients with ITP. Get free access to your research report on RIGL at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Winking is a non-verbal form of communication that involves the rapid closing and opening of one ...
Anti-aging ingredients can prevent signs of aging such as wrinkles, dryness, and sagging of skin. ...
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...View All